Oncotarget

Research Papers:

Overexpression of human β-defensin 2 promotes growth and invasion during esophageal carcinogenesis

Ni Shi _, Feng Jin, Xiaoli Zhang, Steven K. Clinton, Zui Pan and Tong Chen

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2014; 5:11333-11344. https://doi.org/10.18632/oncotarget.2416

Metrics: PDF 1351 views  |   HTML 1769 views  |   ?  


Abstract

Ni Shi1, Feng Jin2, Xiaoli Zhang3, Steven K. Clinton1, Zui Pan2, Tong Chen1

1 Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio

2 Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University, Columbus, Ohio

3 Center for Biostatistics, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, Ohio

Correspondence to:

Dr. Tong Chen, M.D. Ph.D., e-mail: tong.chen@osumc.edu

Key Words: Human β-defensin 2, esophageal squamous cell carcinoma and carcinogenesis

Received: July 07, 2014     Accepted: August 28, 2014     Published: September 05, 2014

ABSTRACT

Human β-defensin 2 (HBD-2) is an antimicrobial peptide produced by mucosal surfaces in response to microbial exposure or inflammatory cytokines. Although HBD-2 is expressed in the esophagus in response to stress and infectious agents, little is known regarding its expression and functional role in esophageal carcinogenesis. In the current investigation, normal esophagus and N-nitrosomethylbenzylamine (NMBA)-induced precancerous and papillomatous lesions of the rat esophagus were characterized for HBD-2 encoding gene Defb4 and protein. HBD-2 was found to be overexpressed in esophagi of rats treated with NMBA compared to animals in control group. Results of Real-time PCR, Western blot and immunohistochemistry demonstrated a positive correlation between the overexpression of HBD-2 and the progression of rat squamous cell carcinogenesis (SCC) in the esophagus. We also observed that HBD-2 is overexpressed in tumor tissues removed from patients with esophageal SCC. Moreover, Defb4 silencing in vitro suppresses the tumor cell proliferation, mobility and invasion in esophageal SCC cell line KYSE-150. The results from this study provide experimental evidence that HBD-2 may play an oncogenic role in the initiation and progression of esophageal SCC and thus serves as a target for chemopreventive and therapeutic interventions.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2416